July 23, 2025

SDC-1 deficiency enhances the pancreatic cancer response to PD-1 antibody by reprogramming tumor microenvironment

View Full Paper

Ask AI

Bookmark

Authors

HYHanteng YangLanzhou University Second Hospital TWTing WangJilin University YWYun WangShanghai Jiao Tong University

Discussion

Member takes

Implication

Targeting SDC-1 improves pancreatic cancer response to PD-1 antibody by reprogramming tumor microenvironment, indicating potential for better immunotherapy outcomes.

Key Points

Core finding shows that SDC-1 deficiency enhances the response to PD-1 antibody in pancreatic cancer.
Data indicates high SDC-1 expression is linked to poor prognosis in pancreatic cancer patients.
Research involved analysis of SDC-1 effects on tumor growth and immune response in mouse models.
Results highlight the importance of tumor microenvironment reprogramming in improving immunotherapy efficacy.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cda2f https://doi.org/10.21203/rs.3.rs-6802997/v1

View Full Paper

Ask AI

Bookmark

Implication

Targeting SDC-1 improves pancreatic cancer response to PD-1 antibody by reprogramming tumor microenvironment, indicating potential for better immunotherapy outcomes.

SDC-1 deficiency enhances the pancreatic cancer response to PD-1 antibody by reprogramming tumor microenvironment

Discussion

Member takes

Implication

Key Points

Cite This Study

SDC-1 deficiency enhances the pancreatic cancer response to PD-1 antibody by reprogramming tumor microenvironment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider